Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEPEZZA Subcutaneous Formulations in Thyroid Eye Disease
NCT06389578Phase 1Completed
- Sponsor
- Amgen
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of teprotumumab in thyroid eye disease (TED) (2 arms), sponsored by Amgen. Primary endpoints: Area Under the Curve, Maximum Serum Concentration and 1 more. Started Jul 2022; status: completed.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06389578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389578.